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Background: Metastatic renal cell carcinoma (mRCC) had been a chemo-refractory disease, but recent advances in
multiple kinase inhibitors such as sunitinib have dramatically changed the clinical course of mRCC. Sunitinib is used
for mRCC chemotherapy based on the favorable results of a recent clinical trial, but specific biomarkers predicting
efficacy and safety are not yet available. Locally advanced bile duct carcinoma (BDC) has generally been treated
with single agent gemcitabine or as doublet therapy with cisplatin. Concomitant occurrence of mRCC and BDC is
extremely rare, and a standard therapeutic strategy has not been established.
Case presentation: A 65-year-old woman was diagnosed as having multiple mRCC and intercurrent, locally advanced
BDC. A single course of combination therapy with sunitinib (25 mg/day, day2-15) and gemcitabine (750 mg/m2, days 1,
8) was administered, and this showed obvious effects, with partial response for mRCC and stable disease for BDC.
However, the patient also experienced severe adverse events, including hematological and various non-hematological
toxicities; the combination therapy was then terminated on day 13 after its initiation. She recovered on day 28 and is
alive 3.5 years after the diagnosis. The plasma trough levels of sunitinib and its active metabolite SU12662 on day 13
were 91.5 ng/mL and 19.2 ng/mL, respectively, which were relatively higher than in previous reports. Analysis of her
single nucleotide polymorphisms (SNPs) detected TC in ABCB1 3435C/T, TC in 1236C/T and TT in 2677G/T, suggesting
a possible TTT haplotype.
Conclusion: A rare case of double cancer of mRCC and BDC was treated by combination chemotherapy. Although
unknown synergistic mechanisms of these agents may be involved, severe toxicities might be possibly associated with
high sunitinib exposure. Further exploration of combination therapy with sunitinib and gemcitabine is required.
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SunitinibBackground
Renal cell carcinoma (RCC) is one of the most serious
urological malignancies. mRCC is initially diagnosed in
30 % of RCC patients, and 20–40 % of curatively operated
RCC patients recur. Recently, new classes of molecular
targeted agents, such as tyrosine kinase inhibitors and
mTOR inhibitors, have become widely used for mRCC.
Sunitinib is an oral tyrosine kinase inhibitor that* Correspondence: keitauch@kyumed.jp
1Department of Medical Oncology, Clinical Research Institute, National
Hospital Organization Kyushu Medical Center, 1-8-1 Jigyouhama, Chuo-ku,
Fukuoka 810-8563, Japan
Full list of author information is available at the end of the article
© 2015 Takayoshi et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.targets vascular endothelial growth factor receptor
(VEGFR)-1, −2 and −3, platelet-derived growth factor
receptor (PDGFR)-α and -β, RET, and c-Kit. It has
often been used for mRCC chemotherapy based on the
favorable results of a phase III clinical trial showing
superiority over interferon alpha [1]. Recent studies,
however, have reported some adverse events including
fatigue, bone marrow suppression, hand-foot syn-
drome, stomatitis, hypertension and hypothyroidism
[1]. In a pivotal study of sunitinib, 38 % of the patients
in the sunitinib group required dose interruptions due
to adverse events, and 32 % required dose reductionsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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markers that can predict the response and adverse
events of sunitinib is urgently needed in order to ob-
tain the optimal effects of this drug.
Biliary tract cancer is rare in the Western countries,
while it is relatively common in Latin America and Asia,
including in Japan [2], and 50–90 % of patients was
diagnosed as having advanced cancer and had a poor
prognosis [3]. Combination chemotherapy consisting of
fluoropyrimidine and gemcitabine has been given not
only for metastatic biliary tract cancer but also for lo-
cally advanced disease. A recent clinical study showed
the efficacy of the combination of gemcitabine and plat-
inum for metastatic biliary tract cancer [4, 5]. While
adverse events of gemcitabine such as myelosuppression,
liver dysfunction, general fatigue, alopecia, and nausea
were often observed, they were mostly tolerable in the
pivotal clinical studies.
Concurrent occurrence of RCC and BDC is extremely
rare. Only two cases have been reported in the literature,
and the biological background of the synchronous pri-
mary malignancy was not clarified [6, 7]. Standard thera-
peutic strategies have generally not been established for
cases of unresectable double primary cancers, and no
chemotherapy was given to the above two cases. In the
present case with concurrent mRCC and BDC, combin-
ation therapy of sunitinib and gemcitabine, which are
both effective agents for each disease, was used, and
both response and various adverse events were seen.
Plasma concentrations of sunitinib and SU12662 wereFig. 1 Images in clinical course: a Chest CT scan of lung metastases before
metastases on day 20 after the administration. c Magnetic resonance chola
common bile duct to bilateral intrahepatic bile ducts (arrow)measured to assess the clinical effects induced by the
combination therapy. Polymorphisms of specific genes
encoding for metabolizing enzymes, efflux transporters,
and drug targets involved in the pharmacokinetics (PK)




A 65-year-old woman was diagnosed with clear cell RCC
in June 1998 and underwent radical left nephrectomy
(pT2N0M0). Her disease status was good risk by Me-
morial Sloan Kettering Cancer Center criteria, and she
was followed closely without therapy after the surgery.
In December 2003, computed tomography (CT) showed
multiple lung metastases. Interferon alfa-2a and sorafe-
nib were administered sequentially. In August 2011, the
tumor eventually progressed (Fig. 1a), and serum biliru-
bin and liver enzymes increased rapidly. Endoscopic
retrograde cholangiopancreatography and magnetic res-
onance cholangiopancreatography examinations revealed
narrowing with an irregular intraductal lumen of the
area from the upper common bile duct to bilateral intra-
hepatic bile ducts (Fig. 1c). Cholangioscopy showed that
the luminal mucosa was circumferentially narrowed with
an irregular reddish surface. These findings were not
likely to be metastatic RCC. She was diagnosed with
upper BDC (T2N1M0). Endoscopic placement of a bil-
iary stent immediately improved the bilirubin and liver
enzyme levels in two days. Surgical resection of herintroduction of sunitinib and gemcitabine. b Chest CT scan of lung
ngiopancreatography image demonstrated narrowing from upper
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because of RCC metastases. Because both cancers had a
strong effect on her prognosis, treatment for both dis-
eases was considered necessary. Thus, treatment consist-
ing of 21-day cycles of sunitinib (25 mg/day; days 2–15
on, days 1 and 16–21 off ) and gemcitabine (750 mg/m2
on days 1 and 8) was initiated [8], and the treatment was
discontinued on day 14 due to various adverse events.
Hematological toxicities of the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI
CTCAE, version 4.0) grade3 thrombocytopenia and neu-
tropenia were noted on day 15. Non-hematological toxic-
ities, depressed consciousness (Grade 1) and fever (Grade
2) were observed. CT and magnetic resonance imaging
(MRI) examination did not suggest organic intracranial le-
sions, and the symptoms improved in 4 days. Lung con-
gestion, respiratory distress, and hypoxemia (Grade 3)
appeared on day 23. Echocardiography showed preserved
cardiac function, and the brain natriuretic peptide (BNP)
concentration was normal. No evidence of infectious
diseases was detected. The other toxicities included syn-
drome of inappropriate secretion of antidiuretic hormone
(SIADH) (Grade 3), increased ALP and γGTP (Grade 3),
increased lipase (Grade 3), and hypothyroidism (Grade 2).
All toxicities improved on day 28. In this case, hand-foot
syndrome and stomatitis were not observed. In terms of
efficacy, CT examination on day 20 showed a significant
decrease in size of the lung metastases (Fig. 1b). The re-
sponse of the lung metastases of RCC and no significant
change for BDC were confirmed on day 35. She had sub-
sequent temsirolimus monotherapy from January 2012
and it achieved tumor control for about 12 months. She is
now under best supportive care 3.5 years after the initial
chemotherapy.
Pharmacokinetic sampling
The plasma levels of sunitinib and SU12662 were analyzed
on days 13, 17, 21, 23, 27, and 33 using the high-
performance liquid chromatography technique [9]. Per-
ipheral blood was obtained before taking sunitinib on days
13, 17, 21, 23, 27 and 33. Then, samples (0.5 ml) were col-
lected in tubes containing ethylenediamine tetraacetic acid
(EDTA). Samples were centrifuged at 3500 rpm at 4 °C
for 10 min, and 0.1 N NaOH was added to the superna-
tants. The compounds were extracted into 3 ml t-butyl
methyl ether (TBME). After agitation for 5 min, the
TBME phase was aspirated and evaporated to dryness
(N2). Aliquots were subjected to high-performance liquid
chromatography.
High-performance liquid chromatography
The chromatographic system consisted of a mobile
phase of a mixture [0.05 M phosphoric buffer (pH 3),
acetonitrile, and B-7 low UV regent (Waters, Milford,MA, USA) at a ratio of 695:300:5] with an ODS column
pumped at a flow rate of 0.3 ml/min and UV/VIS detec-
tion at 431 nm (0–12 min) and 250 nm (12–20 min). Su-
nitinib and SU12662 were purchased from TRC (Toronto
Research Chemicals, Ontario, Canada). The internal stand-
ard was 4-methyl-mexirethyn [9]. The retention times for
SU12662, sunitinib and the internal control were 5.8, 8.3
and 14.8 min, respectively.
DNA sample preparation
The patient gave written, informed consent to participate
in the present study. Genomic DNAs were extracted from
whole blood (500 μL) by the SMITEST EX-R&D Nucleic
Acid Extraction Kit (MBL Co., LTD. Nagoya, Japan). The
concentration of the DNA was adjusted to 50 ng/μL.
Genotyping of SNPs
ABCG2 polymorphism (−15662C/T) was genotyped
using genomic polymerase chain reaction (PCR) and
direct sequencing. Five μL of human genomic DNA
(10 ng/μL), 20 μL of amplification reaction mixture,
and 0.625 units Taq DNA polymerase were placed in
reaction tubes. Amplification of the reaction mixture
was carried out in 50 mM KCl, 10 mM Tris–HCl
(pH 8.3), 1.5 mM MgCl2, 2 % dimethyl sulfoxide (DMSO),
and 0.2 mM dNTPs, 0.2uM each of primers (FP: 5’-
ACCCTGTCTGTCTCTACTAA-3’, RP: 5’-GTGATTA
CATTAAATGAGGTC-3’). PCR reactions were performed
for 40 cycles, with denaturation at 94 °C for 30 s, anneal-
ing at 56 °C for 30 s, and extension at 72 °C for 30 s using
a GeneAmp PCR System 9700 (Life Technologies). The
sequence reaction was run in the ABI 3700 DNA analyzer
(sequencing primer: 5’-CAACTCTCACCTATGAGTGA-
3’) and analyzed using Sequencer computer software
(Gene Codes Corporation, Ann Arbor, MI). Other poly-
morphisms, NR1I3 (5719C/T, 7738A/C, 7837 T/G),
CYP1A1 (2455A/G), ABCG2 (1143C/T, 34G/A, 421C/A),
ABCB1 (3435C/T, 1236C/T, 2677G/T), VEGFR2 (1191C/
T) and FLT3 (738 T/C), were genotyped using the Illu-
mina Human OmniExpress-12 BeadChip (Illumina Inc.,
San Diego, CA). A total of 200 ng of DNA (4 μL at 50 ng/
μL) for the sample was processed according to the Illu-
mina Infinium HD Assay Ultra protocol. BeadChip was
imaged on the Illumina iScan System with iScan Control
Software (v3.3.28). Normalization of raw image intensity
data, genotype clustering, and individual sample genotype
calls were performed using the Illumina GenomeStudio
software (v2011.1), Genotyping Module (v1.9.4).
Results
After administration of 25 mg/day of sunitinib from day
2 to day 13, the plasma trough concentrations were
91.5 ng/mL, decreasing to half on day 17. The plasma
trough concentration of SU12662 was 19.2 ng/mL on
Table 1 SNPs and the genotypes in 13 previously
reported genes
Gene SNPs rs Number Genotype
NR1I3 5719C/T rs2307424 TC
NR1I3 7738A/C rs2307418 AA
NR1I3 7837 T/G rs4073054 TG
CYP1A1 2455A/G rs1048943 AA
ABCG2 1143C/T rs2622604 CC
ABCG2 −15622C/T rs55930652 CC
ABCG2 34G/A rs2231137 GG
ABCG2 421C/A rs2231142 CC
ABCB1 3435C/T rs1045642 TC
ABCB1 1236C/T rs1128503 TC
ABCB1 2677C/T rs2032582 TT
VEGFR2 1191C/T rs2305948 CC
FLT3 738 T/C rs1933437 TC
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patient’s condition gradually recovered following the de-
creases in the plasma levels. This suggests that the high
plasma levels of sunitinib and SU12662 were possibly re-
sponsible for both the efficacy and toxicities observed in
this case.
Gene polymorphisms that have been reported to be
candidate SNPs related to the exposure and metabolism
of sunitinib were analyzed (Table 1). In this case, TC in
ABCB1 3435C/T, TC in 1236C/T and TT in 2677G/T
were detected, and then there were two possibilities:
TTT haplotype and TCT haplotype. CC in ABCG2 type,
CC in -15622C/T, and CC in C421A type were also
detected.
Discussion
Synchronous primary BDC was diagnosed during the
course of metastatic RCC in this case. Although cyto-
logical and histological confirmation for BDC was not
obtained, a series of radiological examinations showed
typical findings of primary BDC rather than mRCC.
RCCs due to hereditary cancer syndromes including
Von Hippel-Lindau disease [10] and Birt-Hogg-Dube
syndrome [11] are known to be associated with colon,
breast, and ovarian cancers. On the other hand, BDC
has been reported to be intercurrent with primary hepa-
tocellular carcinoma [12] However, the synchronous oc-
currence of RCC and BDC is extremely rare, and the
genetic backgrounds are unclear. To the best of our
knowledge, this is the first report of systemic chemother-
apy for a patient with concomitant RCC and BDC.
Combination therapy with sunitinib and gemcitabine,
used in this case, was examined in a phase I trial for pa-
tients with advanced solid tumors [13]. Patients were
given 25–37.5 mg/body daily of sunitinib, and 800 mg/m2
on days 1, 8 and 15 or 675 mg/m2 on days 1 and 8 of gem-
citabine. In all patients groups, grade 3/4 hematologicalFig. 2 Plasma concentrations of Sunitinib (solid circle) and SU12662 (solid
sunitinib administrationtoxicities were observed for neutropenia (54 %), febrile
neutropenia (6 %), thrombocytopenia (18 %), and anemia
(12 %). Michaelson et al. assessed two different schedules
of the combination therapies of (a) sunitinib on a 4-
weeks-on-2-weeks-off schedule (Schedule 4/2) plus
gemcitabine on days 1, 8, 22 and 29, and (b) sunitinib on a
2-weeks-on-1-week-off schedule (Schedule 2/1) plus gem-
citabine on days 1 and 8 [14]. In three patients on Sched-
ule 2/1 with 37.5 mg of sunitinib and 750 mg/m2 of
gemcitabine, two patients showed grade 3 neutropenia
and lymphopenia, and one patient had grade 3 leukopenia.
Increments of the doses of both drugs induced grade 4
hematological and non-hematological toxicities, but no
significant drug-drug interaction was suggested.
A case of pancreatic cancer and RCC that was treated
with combination chemotherapy with 37.5 mg of sunitinibsquare) are shown. Horizontal axis indicates days after initiation of
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on day 1, 8 and 15 was also reported. Two courses of the
therapy achieved high relative dose intensity and partial re-
sponses. Although the dose of gemcitabine was decreased
because of neutropenia, the therapy was safely continued
for 25 weeks [15].
Comparing these reports, the present case experi-
enced relatively intense and various adverse events
even though lower doses of drugs were administered.
Since hematological toxicities and liver toxicity were
also observed in the previous reports, they might be
caused by the combination therapy. On another front,
hypothyroidism was thought to be induced by sunitinib
and pulmonary edema might be caused by the acceler-
ation of vascular endothelial growth factor (VEGF) via
sunitinib.
One of the possible reasons for the enhancement of
adverse events was suggested to be the elevated plasma
concentration of sunitinib. A positive correlation between
plasma concentration of sunitinib and adverse events was
reported by Houk [16]. The previous phase I trial also
showed that sunitinib-induced toxicities appeared in a
dose-dependent manner [13]. Plasma trough concentra-
tions of sunitinib and SU12662 were 91.5 ng/mL and
19.2 ng/mL, respectively, on day 13, when the trough con-
centrations might be in a steady-state. Daily administration
of sunitinib alone in Japanese patients with pancreatic
endocrine tumors showed mean dose-corrected (reference
dose: 37.5 mg) Ctrough values that were within the range of
41.7-53.9 ng/mL for sunitinib, 19.6-25.7 ng/mL for
SU12662, and 62.9-77.5 ng/mL for total drug [17]. In terms
of PK analysis of the combination of sunitinib and gemcita-
bine, the Cmax of sunitinib on day 8 of 50 mg daily admin-
istration was 71.5 ng/mL (CV% 58) (median 60.0) and that
of SU12662 was 27.5 ng/mL (CV% 68) (median 20.9) [14].
Although direct comparison between the values of Cmax
and trough concentration is difficult, and data on the
trough concentration in combination therapy are not avail-
able, the plasma trough concentrations of sunitinib and
SU12662 in the present case were relatively high.
The plasma concentration of sunitinib is regulated by
various factors, including drug-transporters in epithelial
cells of the gastrointestinal tract for absorption of the
drug. Sunitinib was thought to be a substrate for ATP-
binding transporters ABCG2 and ABCB1 [18–20]. It has
been reported that the TTT haplotype of ABCB1 was gen-
erally associated with decreased expression of ABCB1 and
subsequent higher-exposure of its substrates [21, 22]. In
addition, van Erp et al. reported that TTT haplotype was
associated with the risk of hand-foot syndrome with suni-
tinib [23]. However, Garcia-Donas demonstrated that the
ABCB1 polymorphisms were not significantly associated
with the efficacy and toxicities of sunitinib [24]. While the
ABCB1 haplotype of the present case was possibly TTTtype, hand-foot syndrome did not appear. Therefore, the
relationships between ABCB1 polymorphism and the high
plasma concentrations of sunitinib and SU12662 were not
clarified. Sunitinib has also been reported to be a substrate
for ABCG2, and its polymorphism of 421C/A was
correlated with increased exposure of sunitinib [25]. In
addition, TT haplotypes of ABCG2 -15622C/T, and
1143C/T showed increased risks of adverse events [23].
These series of ABCG2 polymorphisms were not found
in the present case.
The drug-metabolizing enzyme CYP3A4 is a key en-
zyme in sunitinib metabolism, and NR1I3 is one of the
regulating factors of CYP3A4 expression [26]. CYP1A1
is known to be associated with the metabolism of tyro-
sine kinase inhibitors. Since these might possibly affect
the plasma concentration of sunitinib, polymorphisms
of these factors were also examined in this case, but no
significant correlation was found. Therefore, polymor-
phisms of specific genes, which might be closely associ-
ated with the PK of sunitinib, could not be eliminated
as possible reasons for the high exposure of sunitinib
and various adverse events; other factors should be
considered.
In the present study, PK analysis of gemcitabine could
not be performed. However, to the best of our know-
ledge, gemcitabine does not induce or inhibit CYP450,
and it is not a substrate of ABCB1 and ABCG2. CYP3A4
has not been known to be involved in gemcitabine me-
tabolism [14]. Therefore, it is less likely that combination
use of gemcitabine might affect the plasma concentra-
tion of sunitinib.
After submission of this manuscript, several clinical
studies employed the combination of sunitinib and gem-
citabine had been published. A randomized phase II
study in advanced pancreatic cancer demonstrated the
combination regimen could not show sufficient superior
efficacy compared to gemcitabine monotherapy but was
associated with more toxicity [27]. Triplet regimens con-
sisting of the combination and cisplatin or capecitabine
in advanced solid tumors exhibited prominent toxicities
suggesting difficulties of further developments of triplet
regimens [28, 29].
Conclusions
An extremely rare case of the concomitant occurrence of
RCC and BDC was treated by combination therapy with
sunitinib and gemcitabine, and clinical response was
achieved. Various adverse events might be associated with
increased plasma concentrations of sunitinib. Possible
mechanisms of high exposure of sunitinib might in-
clude gene polymorphisms of drug-transporters, but
unknown mechanisms induced by the combination use
of two drugs should be investigated. Combination
chemotherapy against double cancers requires more
Takayoshi et al. BMC Cancer  (2015) 15:426 Page 6 of 7careful management, and it is important to identify ad-
equate biomarkers for predicting efficacy and toxicities.
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